Dry eye disease (DED) is a growing concern — which is no surprise given the amount of time most of us spend staring at screens. Affecting up to 700 million people worldwide, DED is responsible for a diminished quality of life, and much like the growing myopia pandemic, it requires ongoing research and development to improve treatment. So when our friends over at Quantel Medical (Cournon-d’Auvergne, France) announced a new intense pulsed light (IPL) technology treatment for DED, we were very interested.
The C.STIM IPL system is described by Quantel Medical as the latest generation of intense pulsed light (IPL) technology designed specifically for DED. IPL treatment has demonstrated considerable efficacy in treating DED and works by warming the meibomian glands to boost the expression of meibum. IPL has been found to improve the function and morphology of meibomian glands and improve DED symptoms in patients.* [You can watch the introduction video.]
The C.STIM IPL system is intended to break the cycle of DED by targeting some of its root causes, namely meibomian gland dysfunction, inflammation and Demodex. What makes the system particularly appealing is not just its primary function, but that it also integrates a number of top-level technological features designed to guarantee efficiency, patient safety and ergonomics, along with plug-and-play functionality. What’s more, thanks to the C.STIM IPL system’s sleek yet robust design, it will fit into almost any clinic with absolute ease.
“Thanks to the unique Stim-ULI technology (Uniform Light Intensity), C.STIM offers the best combination of clinical efficacy and patient comfort,” said Delphine Southon, dry eye product manager at Quantel Medical, in a press release.
“Drawing on Quantel Medical’s years of experience in intense pulsed light in dermatology, we have now developed a new IPL device exclusively for use in ophthalmology, designed and
manufactured by the Lumibird Medical group,” said Jean-Marc Gendre, CEO of Lumibird Medical, which helped to develop the laser. Like Quantel Medical, Lumibird Medical is a member of the Lumibird Group, a leading designer and manufacturer of laser technology. “We are convinced that this new premium product of our dry eye range will bring an innovative therapeutic solution to ophthalmologists confronted with the daily challenge of dry eye treatment,” Gendre added.
If you want to learn more about the C.STIM IPL system, then you’re in luck. Attendees to the upcoming 52nd Royal Australian and New Zealand College of Ophthalmologists (RANZCO 2022) Virtual Meeting can check out the system by visiting the Ellex| Quantel Medical-Lumibird Medical virtual booth. For further information, visit the Quantel Medical website.
*Giannaccare G, Taroni L, Senni C, Scorcia V. Intense Pulsed Light Therapy In The Treatment Of Meibomian Gland Dysfunction: Current Perspectives. Clin Optom (Auckl). 2019;11:113–126.
